ALEXION PHARMACEUTICALS, INC.

Delisted

CIK 899866fmd_0EJCHRGVB7FMQ685FSEV3PVNK1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2008 to Mar 31, 2021, 49 periods

Income Statement · Annual · Millions · USD
Line item	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020
Total revenues	783	1,134	1,551	2,234	2,603	3,084	3,551	4,131	4,991	6,070
Cost of revenue	93	73	178	174	233	258	454	374	395	554
Gross profit	690	1,061	1,374	2,060	2,369	2,826	3,097	3,757	4,597	5,516
Research and development	137	223	317	514	710	757	878	730	886	1,003
Selling, general and administrative	308	385	490	630	863	953	1,094	1,112	1,261	1,400
Total operating expenses	459	657	846	1,191	1,834	2,158	2,470	3,487	2,476	–
Operating income	231	404	528	869	537	667	627	270	2,120	632
Interest expense	1	7	4	3	48	97	98	98	78	105
Interest and investment income	2	2	3	8	9	11	19	65	100	45
Other non-operating income (expense)	–	–	–	–	–	(5)	0	6	36	(3)
Income before taxes	230	398	526	872	498	576	548	242	2,179	569
Income tax expense	54	143	273	215	354	177	105	165	(226)	(34)
Net income from continuing operations	175	255	253	657	144	399	443	78	2,404	603
Net income	175	255	253	657	144	399	443	78	2,404	603
Net income to common shareholders	175	255	253	–	–	–	–	–	–	–